Veralox Therapeutics

FREDERICK, United States · Founded 2018 · $46.6M raised

Headquarters
FREDERICK
Employees
11–50
Founded
2018
Business Model
B2B
Total Funding
$46.6M
Last Round
$5.4M SeedJun 2023
Rounds
5

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Veralox Therapeutics is a clinical-stage biotechnology company developing first-in-class small molecule therapeutics targeting the 12-lipoxygenase (12-LOX) and cGAS pathways to treat immuno-inflammatory, metabolic, and oncological diseases. Its lead candidate, VLX-1005, is a 12-LOX inhibitor being studied for heparin-induced thrombocytopenia, with favorable Phase 1 results reported in 2022. In January 2025 the company expanded its pipeline through an exclusive option to acquire Nudge Therapeutics' preclinical cGAS inhibitor compounds, broadening its inflammatory and autoimmune disease programs.

Summary

Veralox Therapeutics is a Biotech company based in FREDERICK, United States, founded in 2018. It has raised $46.6M in total across 5 rounds, most recently a $5.4M Seed round in Jun 2023. Investors include JDRF T1D Fund, Sanofi Ventures and Pappas Capital.

Tech & App Stack

7 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Extension RoundExtension RoundJun 2023
$24.0M

Sign up to see all 5 events

Funding: Grant through Extension Round. Amounts, valuations, and investors where available.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Veralox Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/veralox-therapeutics"><img src="https://indexed.vc/api/badge/company/veralox-therapeutics" alt="Veralox Therapeutics on Indexed.vc" width="260" height="76" /></a>